Using a tumor-informed approach for molecular residual disease assessment and monitoring
Webinar presenters Noam Z. Drazin, MD, Medical Oncologist, Cedars Sinai Medical Center, and Gregory Botta, MD, PhD, Medical Oncologist-Associate Professor of Medicine, UC San Diego Health, discuss the rapidly evolving role of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and treatment response monitoring. They identify common challenges physicians face when managing their patients with solid tumors, evaluate how a tumor-informed approach may help stratify high-risk patients and inform adjuvant treatment decisions, and review recently presented data from the largest “real world” cohort of CRC patients.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
This on-demand webinar originally broadcast October 13, 2022.
Негізгі бет Optimizing the management of patients with solid tumors
Пікірлер